macrocyclic compounds as inhibitors of hepatitis C virus

CONCERNS macrocyclic compounds of formula (I) wherein the dotted line is a double optional bond; X is N, CH and where X has a double ES C; R1 is OR7 or -NH-SO2R8; R2 IS HY when X is CO CH, R2 may also be (C1-C6); R3 is H, alkyl (C1-C6), cycloalkyl (C3-C7) alkyl or (C1-C6) cycloalkyl- (C1-C6); R4 is aryl or HET, wherein Het is a 5- or 6-membered 1 to 4 heteroatoms selected from N, OUS, optionally substituted; R5 is halo, (C1-C6), hydroxy, (C1-C6), among others; R6 is alkoxy (C1-C6) or dimethylamino; n is 3 to 6. Preferred: 17- [7-methoxy-8-methyl-2- (thiazol-2-yl) quinolin-4-yloxy] -13-methyl-2,14-DIOXO-3, 13-diazatricyclo [13.3.0.0 (4,6)] octadec-7-en-4-carboxylic acid, N- [17- [7-methoxy-8-methyl-2- (thiazol-2yl) quinolin-4- yloxy] -13-methyl-2,14-Dioxo-3,13-diazatricyclo [13.3.0.0 (4,6)] octadec-7-en-4-carbonyl] - (cyclopropyl) sulfonamide, among others. ALSO it REFERS TO A PHARMACEUTICAL COMPOSITION may further comprise another active agent such as ritonavir and method of preparation. These compounds have INHIBITORY ACTIVITY ON REPLICATION HEPATITIS C VIRUS IN THE TREATMENT TO BE USEFUL FOR HEPATITIS C